EZH2 and hepatoblastoma: Several classes of drugs, including DNMT inhibitors (e.g., azacytidine), HDAC inhibitors, and EZH2 inhibitors, are under investigation in preclinical models and clinical trials for hepatoblastoma [3,25,26,27,28,48,58].